Source: Annual Congress 2010 - Experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Karaman, M. Karaman, E. S. Ucan, N. Gokmen, D. Gurel, C. Coker, Y. Adali, O. Yilmaz (Izmir, Turkey). Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure. Eur Respir J 2010; 36: Suppl. 54, 1078

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Effect of normobaric hypoxia on pulmonary hemodynamics in patients with precapillary pulmonary hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics Source: Eur Respir J 2012; 40: 1401-1409 Year: 2012 Two rat models of hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Acute response of iloprost inhalation using the Breelib nebulizer in pulmonary arterial hypertension: the Breelib acute study Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Maladaptive Pulmonary vascular responses to chronic intermittent and sustained hypoxia in a rat hypertension model Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Reversibility of the monocrotaline pulmonary hypertension rat model Source: Eur Respir J 2013; 42: 553-556 Year: 2013 The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig Source: Eur Respir J 2011; 38: 617-627 Year: 2011